Earn CME: https://naccme.com/program/7314
In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice symposium, Dr. John C. Byrd provides an update on BTK inhibitors for CLL.
© 2018 Imedex, an HMP Company
Advertisement